Результаты поиска

Metabolic Reprogramming of Cancer Cells and Therapeutics Targeting Cancer Metabolism.

BackgroundCancer metabolism is a field focused on the unique alterations in metabolic pathways that occur in cancer cells, distinguishing them from the metabolic processes in normal cells.MethodsAn extensive review of the current literature on the metabolic adaptation of cancer cells was carried out in the current study.ResultsThe rapidly proliferating cells require high levels of molecules, such as glucose, amino acids, lipids, and nucleotides, along with increased energy demand (ATP). These requirements are met through alterations in the processes involving glucose, amino acid, lipid, and nu

Совпадение в полном тексте источника
… Germline mutations in the FH gene that deactivate the enzyme and thus alter TCA functioning can cause hereditary leiomyomatosis and renal cell carcinoma (HLRCC). …

Skin manifestations associated with systemic diseases - Part II.

The skin, by reflecting internal processes, externalizes what happens inside the body in many diseases. Thus, the skin, as an organ, extrapolates its functions of protection, barrier and signals the existence of systemic diseases, expanding the importance of the dermatologist beyond the skin surface. Thus, the dermatologist investigates diagnostic hypotheses for conditions related to all systems and refers patients to the appropriate specialty. Combined with examination by a trained eye, the skin, due to its easy access, is still the ideal place for performing biopsies, which often clarify the

Совпадение в полном тексте источника
… papules on the oral mucosa + Lipomas + Hemangiomas | Breast cancer + + | | Thyroid adenocarcinoma + Squamous cell carcinoma of the skin Gardner's syndrome | Epidermoid cysts + fibromas + lipomas + desmoid tumors | Malignant transformation of adenomatous intestinal polyps + CNS neoplasia Hereditary leiomyomatosis …

The skeleton: an overlooked regulator of systemic glucose metabolism in cancer?

Recent discoveries demonstrated the skeleton's role as an endocrine organ regulating whole-body glucose homeostasis. Glucose metabolism is critical for rapid cell proliferation and tumour growth through increasing glucose uptake and fermentation of glucose to lactate despite being in an aerobic environment. This hypothesis paper discusses emerging evidence on how bones can regulate whole-body glucose homeostasis with potential to impact on tumour growth and proliferation. Moreover, it proposes a clinical link between bone glucose metabolism and prognosis of cancer based on recent clinical tria

Совпадение в полном тексте источника
… Similarly, heterogeneous mutations of fumarate hydratase (FH) in the TCA cycle, predispose individuals to multiple cutaneous and uterine leiomyomas, hereditary leiomyomatosis and renal cell cancer ( 32 ). …

Proceedings of the International Cancer Imaging Society (ICIS) 17th Annual Teaching Course : Berlin, Germany. 02 - 04 October 2017

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Metabolic Alterations in Cancer Cells and the Emerging Role of Oncometabolites as Drivers of Neoplastic Change.

The mitochondrion is an important organelle and provides energy for a plethora of intracellular reactions. Metabolic dysregulation has dire consequences for the cell, and alteration in metabolism has been identified in multiple disease states-cancer being one. Otto Warburg demonstrated that cancer cells, in the presence of oxygen, undergo glycolysis by reprogramming their metabolism-termed "aerobic glycolysis". Alterations in metabolism enable cancer cells to gain a growth advantage by obtaining precursors for macromolecule biosynthesis, such as nucleic acids and lipids. To date, several molec

Совпадение в полном тексте источника
… The loss of FH in renal cancer and leiomyomatosis leads to the accumulation of fumarate, and similarly to SDH loss, induces a pseudohypoxic state and accumulation of ROS [ 123 ]. To characterize FH mutations better, a database has been developed [ 124 ]. …

Proceedings of ICIS SGCR-WIRES 2024, held jointly with the 23rd International Cancer Imaging Society Annual Conference, collaborating with the Singapore Radiological Society and College of Radiologists Singapore.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Other rare intravascular tumours and their imaging features, including pulmonary artery sarcomas, intravascular leiomyomatosis, and vascular leiomyosarcomas. Background / Outline: Tumours located within the cardiovascular system are rare, regardless if they originated there or from elsewhere. …

SUBJECT INDEX Volume 125 (JANUARY–JUNE, 2004)

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Supp., vol. 124:232S; clarification, vol. 125:356; bilateral pulmonary nodules secondary to leiomyomatosis, Oct. …

H3 histone methylation landscape in male urogenital cancers: from molecular mechanisms to epigenetic biomarkers and therapeutic targets.

During the last decades, male urogenital cancers (including prostate, renal, bladder and testicular cancers) have become one of the most frequently encountered malignancies affecting all ages. While their great variety has promoted the development of various diagnosis, treatment and monitoring strategies, some aspects such as the common involvement of epigenetic mechanisms are still not elucidated. Epigenetic processes have come into the spotlight in the past years as important players in the initiation and progression of tumors, leading to a plethora of studies highlighting their potential as

Совпадение в полном тексте источника
… For instance, the chromophobe subtype is associated with the Birt-Hogg-Dube syndrome, while type 2 ppRCC is associated with hereditary leiomyomatosis. …

Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence.

Conventional immunotherapy has emerged as a key option for cancer treatment. However, its efficacy has been limited in urological cancers, especially prostate cancer, because of the immunosuppressive tumor microenvironment (TME), difficulty in drug delivery, aberrant immune response, and damage to normal cells. Bispecific antibodies (BsAbs) are engineered proteins with two different antigen-binding domains, designed using different technologies and in various formats. BsAb-based tumor immunotherapy has yielded optimistic results in preclinical and clinical investigations of many tumor types, i

Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer.

Epigenetics shapes all aspects of cancer occurrence and progression. Among them, chromatin methylation is a particularly important regulator of oncogenic processes. The dynamic shifts in methylation can influence the development or death of tumor cells. In the therapeutic context, effectively targeting and modulating DNA, RNA, and histone methylation brings promise for the early detection, prognostic assessment, and treatment of cancer. In particular, novel methylation inhibitors or modulators powerfully kill tumor cells or improve existing therapeutic strategies through different signaling pa

Совпадение в полном тексте источника
… deoxycytidine Advanced solid tumours I, 2017 NCT03366116 DNMT inhibitor Decitabine (5-aza-2′-deoxycytidine [ZdCyd]) Acute myeloid leukemia with complex or monosomal karyotype II, 2017 NCT03080766 DNMT inhibitor Guadecitabine Paraganglioma, gastrointestinal stromal tumours, phaeochromocytoma, hereditary leiomyomatosis … Advanced solid tumours | I, 2017 | NCT03366116 DNMT inhibitor | Decitabine (5-aza-2′-deoxycytidine [ZdCyd]) | Acute myeloid leukemia with complex or monosomal karyotype | II, 2017 | NCT03080766 DNMT inhibitor | Guadecitabine | Paraganglioma, gastrointestinal stromal tumours, phaeochromocytoma, hereditary leiomyomatosis …

Резюме: 32 Второй Конгресс ЭСП и Международный конгресс XXXIII МПД.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Генетическая основа болезни.

Генетика в той или иной степени играет определенную роль во всех заболеваниях. Изменения в нашей ДНК и различия в том, как эта ДНК функционирует (одиночка или комбинация), наряду с окружающей средой (которая включает образ жизни), способствуют болезнетворным процессам. В рамках этого обзора изучается генетическая основа человеческих заболеваний, включая однородные генетические расстройства, хромосомные диспропорции, эпигенетические, раковые и сложные расстройства, и рассматривается вопрос о том, каким образом наше понимание и технологические достижения могут быть использованы для обеспечения н

34th Европейский конгресс патологии - резюме.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Обязательный экзамен по патологии: лишний или необходимый?

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Disorders of the Gastrointestinal System

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Резюме: 31 Европейский конгресс патологии.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

33rd Европейский конгресс патологии - резюме.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Abstracts for NAPCON 2025

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Резюме докладов 51st Конференция Европейского общества генетики человека: плакаты

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Устные бесплатные бумажные сессии.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.